This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Joseph Bubalo, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT00335478
First received: June 8, 2006
Last updated: May 7, 2017
Last verified: May 2017
Results First Received: June 7, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Supportive Care
Conditions: Fever
Sweating
Hot Flashes
Infection
Neutropenia
Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Daptomycin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.

Participant Flow:   Overall Study
    Daptomycin
STARTED   54 
COMPLETED   30 
NOT COMPLETED   24 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.

Baseline Measures
   Daptomycin 
Overall Participants Analyzed 
[Units: Participants]
 30 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      24  80.0% 
>=65 years      6  20.0% 
Age 
[Units: Years]
Median (Standard Deviation)
 50.4  (16.730) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      20  66.7% 
Male      10  33.3% 
Region of Enrollment 
[Units: Participants]
 
United States   30 


  Outcome Measures

1.  Primary:   Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin.   [ Time Frame: Within 72 hours of starting daptomycin ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Joseph Bubalo, PharmD, BCPS, BCOP
Organization: OHSU Knight Cancer Institute
phone: 503-494-1080
e-mail: bubaloj@ohsu.edu



Responsible Party: Joseph Bubalo, OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier: NCT00335478     History of Changes
Other Study ID Numbers: CDR0000476568
OHSU-CPC-05052-L ( Other Identifier: OHSU Knight Cancer Institute )
OHSU-1321 ( Other Identifier: OHSU IRB )
CUBIST-OHSU-CPC-05052-L ( Other Identifier: Cubist Pharmaceuticals )
Study First Received: June 8, 2006
Results First Received: June 7, 2011
Last Updated: May 7, 2017